Design Therapeutics Cash and Investments Reach $219.8 Million
Cash, cash equivalents and investment securities were $219.8M as of December 31, 2025, which the company expects to fund its planned operations into 2029. "The fourth quarter capped a year of strong execution and meaningful progress across our GeneTAC portfolio," said Pratik Shah, chairperson and chief executive officer of Design Therapeutics. "We enter 2026 with three clinical programs advancing toward important milestones, including the planned initiation of patient dosing in our Phase 1 trial of DT-818 in DM1 in the first half of the year and anticipated data from DT-216P2 in FA and DT-168 in FECD in the second half of 2026. Together, these anticipated milestones position us for continued execution of our strategy to build a diversified set of clinical proof-of-concept opportunities for genetic diseases with significant unmet needs."
